What's in Assistance Publique Hopitaux De Marseille's pipeline?

Assistance Publique Hopitaux De Marseille has 60 drugs in our index: 7 marketed, 0 filed, 15 in Phase 3, 13 in Phase 2, 24 in Phase 1.

Which companies overlap with Assistance Publique Hopitaux De Marseille's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, GlaxoSmithKline, AstraZeneca, Celltrion, Eli Lilly and Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/assistance-publique-hopitaux-de-marseille.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Assistance Publique Hopitaux De Marseille — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assistance Publique Hopitaux De Marseille pipeline: 7 marketed, 0 filed, 15 Phase 3, 13 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 15 Phase 3 13 Phase 2 24 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
azacytidine	azacytidine	marketed		DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A	Oncology
Azithromycine	Azithromycine	marketed			Other
blood samples	blood samples	marketed
Treatment with Amikacin	Treatment with Amikacin	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit	Infectious Disease
Aciclovir	Aciclovir	marketed		Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase	Infectious Disease
Nasal swab	Nasal swab	marketed			Diagnostics
NIMBEX	NIMBEX	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor	Anesthesia
Durvalumab (MEDI4736)	Durvalumab (MEDI4736)	phase 3	PD-L1 inhibitor	PD-L1	Oncology
BYETTA treatment	BYETTA treatment	phase 3	GLP-1 receptor agonist	GLP-1R	Diabetes
Treatment BY METROMIDAZOLE	Treatment BY METROMIDAZOLE	phase 3	nitroimidazole antibiotic		Infectious diseases
Gymiso®	Gymiso®	phase 3	Progesterone receptor antagonist	Progesterone receptor (PR)	Reproductive Health / Obstetrics
treatment Doxorubicin	treatment Doxorubicin	phase 3	Anthracycline chemotherapy agent	DNA (intercalating agent); Topoisomerase II	Oncology

Therapeutic area mix

Oncology · 5
Other · 4
Immunology · 2
Neurology · 2
Reproductive Health / Obstetrics · 2
Infectious Disease · 2
Anesthesia · 1
Urology · 1
Cardiovascular · 1
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
GlaxoSmithKline · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Celltrion · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
· 2 shared drug classes
Pfizer · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Assistance Publique Hopitaux De Marseille:

Cite this brief

Drug Landscape (2026). Assistance Publique Hopitaux De Marseille — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/assistance-publique-hopitaux-de-marseille. Accessed 2026-05-17.